Textbook of Personalized Medicine - Second Edition [2015]

711

PCR biochip technology , 47–48
protein biochips
developments in , 55
for personalized medicine , 55–56
ProteinChip , 53–54
proteomic pattern analysis , 54–55
role of , 45
SNPs, detection of ( see Single nucleotide
polymorphisms (SNP))
Bioinformatics , 18
biomarker data , 95
EHRs ( see Electronic health records
(EHRs))
health information management , 637
LARaLink 2.0 , 636
REFST technology , 636–637
software tools , 635–636
wireless non-invasive biosensors , 636
BioIT Alliance , 597–598
Biological therapies
antisense therapy , 194–195
microRNAs (miRNAs) , 196
RNA interference , 195–196
cell therapy , 190–191
autologous tissue and cell transplants , 191
cloning and , 192
stem cells ( see Stem cells)
gene therapy , 193–194
personalized cancer vaccines , 194
recombinant human proteins , 189–190
therapeutic monoclonal antibodies , 190
Biomarkers
ADRs , 118
alpha1-antitrypsin , 522
bioinformatics , 95
cancer therapy
HER-2/neu oncogene , 220
L-ASP treatment , 220–221
oncogene GOLPH3 , 221
PARE , 222
predictive markers , 221
VeraTag™ assay system , 223
cardiovascular disorders , 488
chromagranin A , 523
clinical trials, Bayesian approach , 95–96
defi nition of , 91
DMET™ Plus biomarker panel , 112–113
DNA repair pathways , 208
Down’s syndrome , 534–535
drug labels, pharmacogenomic information
in , 134–140
drug rescue , 93
drug toxicity , 131

of epilepsy , 426–427

FDA , 669, 671

gene expression signatures , 92

in HIV/AIDS management , 397–398

HPV-related head and neck cancer , 325–326

IBD , 567

interstitial lung disease , 525–526

LSDs , 537–538

of lung cancer , 352–353

lung failure , 522

MAb drug development , 93

metabolomics

advantages of , 172

data processing and validation , 174

FT-ICR , 172

GC-TOF-MS applications , 172

identifi cation and pattern recognition ,

173–174

lipid profi ling , 173

urinary profi ling, capillary

electrophoresis , 172–173

in monitoring grafted patients , 561–563

monitoring treatment response , 94

muscular dystrophy , 535–536

of pancreatic cancer , 358–359

personalized medicine, impact on , 91, 92

pharmacogenetic test , 91

pharmacogenomic test , 92

phenylketonuria , 536

psoriasis , 536–537

pulmonary disorders ( see Pulmonary

disorders)

radiation-specifi c biomarkers , 255

response to antidepressant therapy , 468, 469

for rheumatoid arthritis , 556

for SLE , 554

Biomarkers of Anti-TNF-α Therapy Effi cacy

in Rheumatoid arthritis to defi ne

Unresponsive Patients

(BATTER-UP) , 556

Biosensors

characteristics , 52

DNA biosensors , 53

POC diagnosis , 84–85

principle of , 52

wireless non-invasive biosensors , 636

Biotechnology companies , 597

Biotechnology Industry Organization ,

663–664

BIOVAXID™ , 246, 252

Bisphosphonates , 572, 595

Bloodchip , 563

Blood transfusions , 563

Index